Diabetes Research and Clinical Practice
Volume 86, Issue 1 , Pages 74-81 , October 2009

Effect of tight control of HbA1c and blood pressure on cardiovascular diseases in type 2 diabetes: An observational study from the Swedish National Diabetes Register (NDR)

  • Jan Cederholm

      Affiliations

    • Department of Public Health and Caring Sciences/Family Medicine and Clinical Epidemiology, Uppsala University, Uppsala, Sweden
    • Corresponding Author InformationCorresponding author at: Family Medicine and Clinical Epidemiology Section, Department of Public Health and Caring Sciences, Uppsala University, Uppsala Science Center, Dag Hammarskjölds väg 14B, S-751 85 Uppsala, Sweden. Tel.: +46 0709 507850; fax: +46 18 541097.
    • ,
  • Björn Zethelius

      Affiliations

    • Department of Public Health and Caring Sciences/Geriatrics, Uppsala University, Uppsala, Sweden
    • ,
  • Peter M. Nilsson

      Affiliations

    • Department of Clinical Sciences, Lund University, University Hospital, Malmö, Sweden
    • ,
  • Katarina Eeg-Olofsson

      Affiliations

    • Department of Medicine, Sahlgrenska University Hospital, Göteborg University, Göteborg, Sweden
    • ,
  • Björn Eliasson

      Affiliations

    • Department of Medicine, Sahlgrenska University Hospital, Göteborg University, Göteborg, Sweden
    • ,
  • Soffia Gudbjörnsdottir

      Affiliations

    • Department of Medicine, Sahlgrenska University Hospital, Göteborg University, Göteborg, Sweden
    • ,
  • on behalf of the Swedish National Diabetes Register

Received 10 March 2009 ,Revised 22 June 2009 ,Accepted 13 July 2009.

References 

  1. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412–419
  2. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998;316:823–828
  3. UK Prospective Diabetes Study Group . Tight blood pressure control and risk of macrovascular complications in type-2 diabetes: UKPDS 38. BMJ. 1998;317:703–713
  4. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755–1762
  5. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators . Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO HOPE substudy. Lancet. 2000;355:253–259
  6. Blood Pressure Lowering Treatment Trialists’ Collaboration . Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Arch. Intern. Med. 2005;165:1410–1419
  7. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829–840
  8. Avogaro A, Giorda C, Maggini M, Mannucci E, Raschetti R, Lombardo F, et al. Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care. 2007;30:1241–1247
  9. Gerstein HC, Pogue J, Mann JF, Lonn E, Dagenais GR, McQueen M, et al. The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia. 2005;48:1749–1755
  10. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–412
  11. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann. Intern. Med. 2004;141:421–431
  12. The Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993;329:977–986
  13. UK Prospective Diabetes Study (UKPDS) Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  14. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil AW. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 2008;359:1577–1589
  15. Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 2008;358:2545–2559
  16. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 2008;358:2560–2572
  17. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with Type 2 diabetes. N. Engl. J. Med. 2009;360:129–139
  18. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N. Engl. J. Med. 2008;358:580–591
  19. Gudbjörnsdottir S, Cederholm J, Nilsson PM, Eliasson B. The National Diabetes Register in Sweden: an implementation of the St. Vincent declaration for quality improvement in diabetes care. Diabetes Care. 2003;26:1270–1276
  20. Cederholm J, Eliasson B, Nilsson PM, Weiss L, Gudbjörnsdottir S, for the steering committee of the Swedish National Diabetes Register . Microalbuminuria and risk factors in type 1 and type 2 diabetic patients. Diabetes Res. Clin. Pract. 2005;67:258–266
  21. Eliasson B, Cederholm J, Nilsson P, Gudbjörnsdottir S, for the steering committee of the Swedish National Diabetes Register . The gap between guidelines and reality: Type 2 diabetes in a national diabetes register 1996–2003. Diabet. Med. 2005;22:1420–1426
  22. Nilsson PM, Cederholm J, Gudbjörnsdottir S, Eliasson B, for the Steering Committee of the Swedish National Diabetes Register . Predictors of successful long-term blood pressure control in patients with diabetes–data from the Swedish National Diabetes Register (NDR). J. Hypertens. 2005;23:2305–2311
  23. Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Nilsson PM, Gudbjörnsdottir S, et al. Risk prediction of cardiovascular disease in type 2 diabetes. Diabetes Care. 2008;31:2038–2043
  24. Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Nunez L, Gudbjörnsdottir S, et al. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13.087 patients. Diabetologia. 2009;52:65–73
  25. Hoelzel W, Weykamp C, Jeppsson JO, Miedema K, Barr JR, Goodall I, et al. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin. Chem. 2004;1:166–174
  26. Merlo J, Lindblad U, Pessah-Rasmussen H, Hedblad B, Rastam J, Isacsson SO, et al. Comparison of different procedures to identify probable cases of myocardial infarction and stroke in two Swedish prospective cohort studies using local and national routine registers. Eur. J. Epidemiol. 2000;16:235–243
  27. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA project. Registration procedures, events rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation. 1994;90:583–612
  28. Spiegelman D, Hertzmark E, Wand HC. Point and interval estimates of partial population attributable risks in cohort studies: examples and software. Cancer Causes Control. 2007;18:571–579
  29. Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur. Heart J. 2007;28:88–136
  30. UK Prospective Diabetes Study (UKPDS) Group . Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865
  31. Intensive BP and glucose-lowering additive in diabetics: ADVANCE, http://www.theheart.org/article/902457.do, September 8, 2008.
  32. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291:335–342
  33. Gudbjörnsdottir S, Eeg-Olofsson K, Cederholm J, Zethelius B, Eliasson B, Nilsson PM. Risk factor control in patients with type 2 diabetes and coronary heart disease: findings from the Swedish National Diabetes Register (NDR). Diabet. Med. 2009;26:53–60
  34. Lind L, Lithell H, Pollare T. Is it hyperinsulinemia or insulin resistance that is related to hypertension and other metabolic cardiovascular risk factors?. J. Hypertens. 1993;11(Suppl.):S11–S16
  35. Sung KC, Kim BJ, Kim BS, Kang JH, Lee MH, Park JR, et al. In normoglycemic Koreans, insulin resistance and adipocity are independently correlated with high blood pressure. Circ. J. 2004;8:898–902
  36. Pollare T, Lithell H, Berne C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism. 1990;39:167–174
  37. Mogensen CE. Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes. J. Intern. Med. 2003;254:45–66
  38. Parving H-H, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 2001;345:870–876

PII: S0168-8227(09)00302-7

doi: 10.1016/j.diabres.2009.07.003

Diabetes Research and Clinical Practice
Volume 86, Issue 1 , Pages 74-81 , October 2009

Article Tools